Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Short bursts of motion throughout the day can help
only oral GLP-1 FDA-approved to reduce the risk of MACE in adults with type 2 diabetes mellitus (T2DM) New indication: to reduce the risk of MACE (CV death, non-fatal MI or non-fatal stroke) in adults with T2DM who are at high risk for these events Administered orally once daily with dosage dependent on if using the R1 or R2 formulation Other indication: as an adjunct to diet and exercise to improve glycemic control in adults with T2DM First generic drug launches Sept
10.3389/fphar.2012.00119 Front Pharmacol
Takes 90 seconds 100% private free Your plan includes Everything
DSIP is not an approved medicine in any jurisdiction and is supplied as lyophilised powder for in-vitro laboratory research only
US$ 21.40
US$ 28.88
US$ 25.61
US$ 29.06
US$ 26.18
US$ 22.43
